KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gains from Investment Securities (2020 - 2025)

Recursion Pharmaceuticals' Gains from Investment Securities history spans 6 years, with the latest figure at -$2.9 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 82.96% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$9.5 million, up 41.55%, while the annual FY2025 figure was -$9.5 million, 41.55% up from the prior year.
  • Gains from Investment Securities reached -$2.9 million in Q4 2025 per RXRX's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.9 million in Q2 2024 to a low of -$17.0 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is -$1.3 million, with a median of -$427500.0 recorded in 2022.
  • The largest YoY upside for Gains from Investment Securities was 25926.09% in 2024 against a maximum downside of 1233.36% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $2.9 million in 2021, then plummeted by 115.41% to -$453000.0 in 2022, then soared by 430.91% to $1.5 million in 2023, then crashed by 1233.36% to -$17.0 million in 2024, then surged by 82.96% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Gains from Investment Securities are -$2.9 million (Q4 2025), $2.4 million (Q3 2025), and -$4.7 million (Q2 2025).